PL EN


Preferences help
enabled [disable] Abstract
Number of results
2009 | 56 | 1 | 135-142
Article title

Cytotoxicity and inhibitory properties against topoisomerase II of doxorubicin and its formamidine derivatives

Content
Title variants
Languages of publication
EN
Abstracts
EN
This work was undertaken to compare cytotoxicity, DNA damaging properties and effect on DNA cleavage by topoisomerase II of the anthracycline drug doxorubicin (DOX) and its two derivatives with a formamidino group containing a cyclic amine moiety such as morpholine (DOXM) or hexamethyleneimine (DOXH). The tetrazolium dye colorimetric assay was used to determine the cytotoxic activity of anthracyclines toward L1210 leukemia cells. DNA damage was measured by alkaline elution technique. The effect of anthracyclines on DNA cleavage was studied in a cell-free system containing supercoiled pBR322 DNA and purified human topoisomerase II. The cytotoxicity data and the results of studies on the mechanism of DNA break formation by anthracyclines at the cellular level and in the cell-free system showed that the presence of the formamidino group in the doxorubicin molecule reduced its ability to stimulate DNA cleavage by DNA topoisomerase II. Conclusion: DNA topoisomerase II is not a primary cellular target for DOXM or DOXH. An advantageous feature of formamidinoanthracyclines is their mechanism of cytotoxic action which is not related to the inhibition of DNA topoisomerase II. Therefore this class of anthracyclines seems to be a good source for selection of an anticancer drug directed toward cancer cells with the developed multidrug resistance attributed to the presence of altered DNA topoisomerase II.
Year
Volume
56
Issue
1
Pages
135-142
Physical description
Dates
published
2009
received
2008-11-02
revised
2008-12-16
accepted
2009-02-12
(unknown)
2009-02-23
References
  • Bakker M, Renes J, Groenhuijzen A, Visser P, Timmer-Bosscha H, Müller M, Groen HJ, Smit EF, de Vries EG (1997) Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines. Int J Cancer 73: 362-366.
  • Battisti RF, Zhong Y, Fang L, Gibbs S, Shen J, Zhang G, Sun D (2007) Modifying the sugar moieties of daunorubicin overcomes P-gp-mediated multidrug resistance. Mol Pharm 4: 140-153.
  • Capranico G, Supino R, Binaschi M, Capolongo L, Grandi M, Suarato A, Zunino F (1994) Influence of structural modifications at the 3' and 4' positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance. Mol Pharmacol 45: 908-915.
  • Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of tetrazolium-based semiautomatic colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942.
  • Ciesielska E, Studzian K, Wasowska M, Oszczapowicz I, Szmigiero L (2005) Cytotoxicity, cellular uptake and DNA damage by daunorubicin and its new analogues with modified daunosamine moiety. Cell Biol Toxicol 21: 139-147.
  • Cutts SM, Swift LP, Rephaeli A, Nudelman A, Phillips DR (2005) Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde. Curr Med Chem Anticancer Agents 5: 431-447.
  • Cvetkovic RS, Scott LJ (2005) Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 65: 1005-1024.
  • Dal Ben D, Palumbo M, Zagotto G, Capranico G, Moro S (2007) DNA topoisomerase II structures and anthracycline activity: insight into ternary complex formation. Curr Pharm Des 13: 2766-2780.
  • Danesi R, Agen C, Grandi M, Nardini V, Bevilacqua G, Dell Tacca M (1993) 3'-Deamino-3'-(2-methoxy-4-morpholinyl)-doxorubicin (FCE23762): a new anthracycline derivative with enhanced cytotoxicity and reduced cardiotoxicity. Eur J Cancer 29A: 1560-1565.
  • Elliott P (2006) Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 33:,(3 Suppl 8), S2-7.
  • Grout RJ (1975) Biological reactions and pharmaceutical uses of imidic acid derivatives. In The Chemistry of Amidines and Imidate. Patai S, ed, pp 255-228. Wiley & Sons, New York.
  • Kohn KW (1991) Principles and practice of DNA filter elution. Pharmacol Ther 49: 55-77.
  • Jakubowska J, Stasiak M, Szuławska A, Bednarek A, Czyz M (2007) Combined effects of doxorubicin and STI571 on growth, differentiation and apoptosis of CML cell line K562. Acta Biochim Polon 54: 839-846.
  • Larsen AK, Escarqueil AE, Skladanowski A (2003) Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 99: 167-181.
  • Lehne G (2000) P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets 1: 85-99.
  • Lemke K, Poindessous V, Skladanowski A, Larsen AK (2004) The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties. Mol Pharmacol 66: 1035-1042.
  • Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229.
  • Nadas J, Sun D (2006) Anthracyclines as effective anticancer agents. Expert Opin Drug Discov 1: 539-548.
  • Oszczapowicz I, Wąsowska M, Oszczapowicz J, Owoc A, Dominiczak E, Wietrzyk J, Opolski A (2005) New derivatives of anthracycline antibiotics, method of synthesis and pharmaceutical agents containing them. Polish Patent Application P. 381387.
  • Pawłowska J, Tarasiuk J, Borowski J, Wąsowska M, Osz­czapowicz I, Wolf CR (2000) The ability of new formamidine sugar-modified derivatives of daunorubicin to stimulate free radical formation in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase and xanthine oxidase. Acta Biochim Polon 47: 141-147.
  • Piestrzeniewicz MK, Wilmanska D, Szemraj J, Studzian K, Gniazdowski M (2004) Interactions of novel morpholine and hexamethylene drivatives of anthracycline antibiotics with DNA. Z Naturforsch 59c: 739-748.
  • Renes J, de Vries EGE, Jansen PLM, Müller M (2000) The (patho)physiological functions of the MRP family. Drug Resist Updat 3: 289-302.
  • Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D, Bosia A (2005) Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 65: 516-525.
  • Szuławska A, Gniazdowski M, Czyż M (2005) Sequence specificity of formaldehyde-mediated covalent binding of anthracycline derivatives to DNA. Biochem Pharmacol 69: 7-18.
  • Szuławska A, Arkusińska J, Czyż M (2007) Accumulation of gamma-globin mRNA and induction of irreversible erythroid differentiation after treatment of CML cell line K562 with new doxorubicin derivatives. Biochem Pharmacol 73: 175-184.
  • Wąsowska M, Oszczapowicz I, Wietrzyk J, Opolski A, Madej J, Dzimira S, Oszczapowicz J (2005) Influence of the structure of new anthracycline antibiotics on their biological properties. Anticancer Res 25: 2043-2048.
  • Wąsowska M, Wietrzyk J, Opolski A, Oszczapowicz J, Osz­czapowicz I (2006) Effect of structural modification of anthracyclines on the ability to overcome drug resistance of cancer cells. Anticancer Res 26: 2009-2012.
  • Wąsowska-Łukawska M, Wietrzyk J, Opolski A, Oszczapowicz J, Oszczapowicz I (2007) Biological properties of new derivatives of daunorubicin. In vivo 21: 413-416.
  • Zwelling LA, Michaels S, Erickson LC, Ungerleider RS, Nichols M, Kohn KW (1981) Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino)methanesulfon-m-anisidide and adriamycin. Biochemistry 20: 6553-6563.
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv56p135kz
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.